Mayne Pharma spends $50 million on rights to GSK dermatology assets

Australia-headquartered Mayne Pharma (ASX: MYX) says it has acquired a portfolio of on-market dermatology foam assets from UK pharma major GlaxoSmithKline (LSE: GSK) for $50.1 million.

These assets include US rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam. Under the terms of the agreement Mayne Pharma will acquire the approved regulatory filings, trademarks, marketing materials, select product inventory, related medical and technical data and will acquire or obtain licenses for related patents.

Fabior (tazarotene) Foam, 0.1% is a patent-protected topical product indicated for the treatment of acne, the largest dermatology indication in the US affecting up to 50 million Americans every year. Sorilux (calcipotriene) Foam, 0.005% is a patent-protected topical product indicated for mild to moderate plaque psoriasis affecting up to 6 million Americans each year1.